IR contact detailsRoman Akbar-HaaseDirector Investor Relations and Business Developmente: ir@moonlaketx.com Upcoming events May 19 2026 H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq, New York City, NY May 19 - May 20 2026 RBC Capital Markets Global Healthcare Conference, New York City, NY Jun 3 - Jun 6 2026 EULAR (European Alliance of Associations for Rheumatology) congress, London, UK View All Events View All Events + Corporate presentations MoonLake Investor Day (Feb 2026) Clinical Data Update (Nov 2025) View All Presentations View All Presentations + Latest press releases May 10 2026 MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results Mar 28 2026 MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting Feb 22 2026 MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results View All News View All Press Releases +
May 10 2026 MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
Mar 28 2026 MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Feb 22 2026 MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results